These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

262 related articles for article (PubMed ID: 11232738)

  • 1. Antipsychotic medications and the elderly: effects on cognition and implications for use.
    Byerly MJ; Weber MT; Brooks DL; Snow LR; Worley MA; Lescouflair E
    Drugs Aging; 2001; 18(1):45-61. PubMed ID: 11232738
    [TBL] [Abstract][Full Text] [Related]  

  • 2. An open, large, 6-month naturalistic study of outcome in schizophrenic outpatients, treated with olanzapine.
    Krzystanek M; Krupka-Matuszczyk I
    Hum Psychopharmacol; 2011 Jan; 26(1):81-5. PubMed ID: 23055416
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Using antipsychotic agents in older patients.
    Alexopoulos GS; Streim J; Carpenter D; Docherty JP;
    J Clin Psychiatry; 2004; 65 Suppl 2():5-99; discussion 100-102; quiz 103-4. PubMed ID: 14994733
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Atypical antipsychotics: mechanism of action.
    Seeman P
    Can J Psychiatry; 2002 Feb; 47(1):27-38. PubMed ID: 11873706
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Second-generation (atypical) antipsychotics and metabolic effects: a comprehensive literature review.
    Newcomer JW
    CNS Drugs; 2005; 19 Suppl 1():1-93. PubMed ID: 15998156
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A model of anticholinergic activity of atypical antipsychotic medications.
    Chew ML; Mulsant BH; Pollock BG; Lehman ME; Greenspan A; Kirshner MA; Bies RR; Kapur S; Gharabawi G
    Schizophr Res; 2006 Dec; 88(1-3):63-72. PubMed ID: 16928430
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Upcoming agents for the treatment of schizophrenia: mechanism of action, efficacy and tolerability.
    Bishara D; Taylor D
    Drugs; 2008; 68(16):2269-92. PubMed ID: 18973393
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effects of newer antipsychotics on extrapyramidal function.
    Tarsy D; Baldessarini RJ; Tarazi FI
    CNS Drugs; 2002; 16(1):23-45. PubMed ID: 11772117
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Second-generation antipsychotic effect on cognition in patients with schizophrenia--a meta-analysis of randomized clinical trials.
    Nielsen RE; Levander S; Kjaersdam Telléus G; Jensen SO; Østergaard Christensen T; Leucht S
    Acta Psychiatr Scand; 2015 Mar; 131(3):185-96. PubMed ID: 25597383
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cognitive and psychomotor effects of risperidone in schizophrenia and schizoaffective disorder.
    Houthoofd SA; Morrens M; Sabbe BG
    Clin Ther; 2008 Sep; 30(9):1565-89. PubMed ID: 18840365
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Behavioural pharmacology of the new generation of antipsychotic agents.
    Moore NA
    Br J Psychiatry Suppl; 1999; (38):5-11. PubMed ID: 10884895
    [TBL] [Abstract][Full Text] [Related]  

  • 12. On the trail of a cognitive enhancer for the treatment of schizophrenia.
    Stip E; Chouinard S; Boulay LJ
    Prog Neuropsychopharmacol Biol Psychiatry; 2005 Feb; 29(2):219-32. PubMed ID: 15694228
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Relationship between dopaminergic and serotonergic neuronal activity in the frontal cortex and the action of typical and atypical antipsychotic drugs.
    Ichikawa J; Meltzer HY
    Eur Arch Psychiatry Clin Neurosci; 1999; 249 Suppl 4():90-8. PubMed ID: 10654114
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Advances in pharmacotherapy of psychotic disorders in the elderly.
    Kirkwood CK; Givone DM
    Consult Pharm; 2003 Jun; 18(6):539-50. PubMed ID: 16563063
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Benefit-risk assessment of atypical antipsychotics in the treatment of schizophrenia and comorbid disorders in children and adolescents.
    Toren P; Ratner S; Laor N; Weizman A
    Drug Saf; 2004; 27(14):1135-56. PubMed ID: 15554747
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Atypical antipsychotics. Part I: Pharmacology, pharmacokinetics, and efficacy.
    Markowitz JS; Brown CS; Moore TR
    Ann Pharmacother; 1999 Jan; 33(1):73-85. PubMed ID: 9972387
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A comparative review of new antipsychotics.
    Blin O
    Can J Psychiatry; 1999 Apr; 44(3):235-44. PubMed ID: 10225124
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Atypical antipsychotics for the treatment of delirious elders.
    Ozbolt LB; Paniagua MA; Kaiser RM
    J Am Med Dir Assoc; 2008 Jan; 9(1):18-28. PubMed ID: 18187109
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Olanzapine: an updated review of its use in the management of schizophrenia.
    Bhana N; Foster RH; Olney R; Plosker GL
    Drugs; 2001; 61(1):111-61. PubMed ID: 11217867
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cognitive function and social abilities in patients with schizophrenia: relationship with atypical antipsychotics.
    Tyson PJ; Laws KR; Flowers KA; Tyson A; Mortimer AM
    Psychiatry Clin Neurosci; 2006 Aug; 60(4):473-9. PubMed ID: 16884450
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.